Peanut OIT in Adults: Breakthroughs from the GUPI Trial
- Allergy Aware UK
- Apr 26
- 1 min read
For the first time, adult peanut oral immunotherapy has shown promise: 67% of study participants now tolerate multiple peanuts daily. Clinical, but hopeful news.
Who this helps: Peanut-allergic adults and their families.
Key takeaways
First exclusively adult trial in UK (GUPI), with promising desensitisation results.
2 in 3 adults tolerated ~5 peanuts daily—dramatic quality-of-life improvement.
This is research, not yet NHS-offered treatment—but suggests future pathways.
What’s changing
The GUPI adult trial, led by King’s College London and Guy’s & St Thomas’, found 67% of 21 participants could tolerate the equivalent of 4–5 peanuts after supervised oral doses.
Practical takeaways
Keep allergy action plans up to date—even as research progresses.
Follow Allergy UK (#These3Things) updates—they’re actively discussing results
Share your story–community strength matters.
When to seek help:Always use your auto-injector and call 999 if exposure causes serious symptoms.
References
Anaphylaxis UK (2025) Immunotherapy for peanut-allergic adults: GUPI trial results. Available at: https://www.anaphylaxis.org.uk/immunotherapy-for-peanut-allergic-adults
King’s College London (2025) Daily doses of peanuts tackle allergic reactions in adults. Available at: https://www.kcl.ac.uk/news/daily-doses-of-peanuts-tackle-allergic-reactions-in-adults
CEA (2025) Peanut oral immunotherapy in adults (GUPI): clinical trial report. Available at: https://onlinelibrary.wiley.com/doi/10.1111/cea.14491
Comments